RIPK3 promotes skin inflammation by enhancing IL-36α signaling and necroptosis in keratinocytes

作者：Qingqing Li, Tao Yang, Jin-jin Ren, Zhi-zhen Hui, Shu-yue Lei, Chunlan Feng, Xiaoqian Yang, Wei Tang · 发表于：Cell Death and Disease · 年份：2025 · DOI：10.1038/s41419-025-08096-9 · 被引用次数：2 · 研究领域：Inflammasome and immune disorders、Psoriasis: Treatment and Pathogenesis、Cell death mechanisms and regulation

Psoriasis is a chronic inflammatory skin disease characterized by complex pathogenesis involving multiple factors. Keratinocytes, as key structural components, play a critical role in immune regulation and contribute to disease progression through interactions with various immune cells. Receptor-interacting protein kinase 3 (RIPK3) is well-known for its role in necroptosis, acting alongside RIPK1 and mixed-lineage kinase domain-like (MLKL). While studies have shown that inhibitors of necroptosis could alleviate psoriasis-like skin inflammation, direct genetic evidence of RIPK3 is lacking. Furthermore, recent studies have highlighted RIPK3's independent biological functions beyond necroptosis, yet its pathological role in inflammatory skin disease remains poorly understood. This study aimed to elucidate the pathological role of RIPK3 in the progression of skin inflammation, particularly in keratinocytes. We demonstrated that RIPK3 expression was significantly upregulated in psoriasis patients and mice with imiquimod (IMQ)-induced skin inflammation. Importantly, keratinocyte-specific knockout of RIPK3 using gene-editing tools significantly alleviated IMQ-induced skin inflammation in mice. Interestingly, the absence of RIPK3 not only inhibited necroptosis and associated inflammatory responses but also significantly reduced interleukin-36α (IL-36α) expression in keratinocytes. IL-36α, known to drive skin inflammation, promote immune cell recruitment, and disrupt the epidermal bar...